All In Biotech

Free tool

FAERS Monitor: Ridaura

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 018689 or its brand name (Ridaura, Auranofin). Reports on generic versions are filed under their own applications.

Reports

205

Serious

156

76% of reports

Hospitalization

94

Death reported

28

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug hypersensitivity18
  • drug ineffective16
  • nausea15
  • anaemia12
  • fall11
  • fatigue11
  • pneumonia11
  • pain10
  • pyrexia9
  • myocardial infarction8
  • rheumatoid arthritis8
  • abdominal pain upper7
  • constipation7
  • cough7
  • dizziness7

Reports by year received

View as table
YearReports
200420
200521
200611
20078
200815
200914
20108
20119
20127
201311
20149
20151
201610
201718
201822
201910
20204
20214
20231
20242

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,954 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
drug hypersensitivitySignal189.56.1130
rheumatoid arthritisSignal87.23.737
anaemiaSignal126.53.750
myocardial infarctionSignal84.72.420
abdominal pain upperSignal73.51.710
pneumoniaSignal113.52.017
fallSignal113.41.916
constipationSignal73.31.69
pyrexiaSignal92.71.48
coughSignal72.61.25
nausea151.91.26
pain101.70.92
fatigue111.40.81
dizziness71.40.71
drug ineffective161.20.81

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.